scholarly journals Influences of ABO blood group, age and gender on plasma coagulation factor VIII, fibrinogen, von Willebrand factor and ADAMTS13 levels in a Chinese population

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e3156 ◽  
Author(s):  
Zongkui Wang ◽  
Miaomiao Dou ◽  
Xi Du ◽  
Li Ma ◽  
Pan Sun ◽  
...  
Keyword(s):  
Blood Group ◽  
Plasma Levels ◽  
Chinese Population ◽  
Coagulation Factor ◽  
Abo Blood Group ◽  
Strongly Correlated ◽  
Age And Gender ◽  
And Gender ◽  
Von Willebrand ◽  
Willebrand Factor

BackgroundABO blood group is a hereditary factor of plasma levels of coagulation factor VIII (FVIII) and von Willebrand factor (VWF). Age and gender have been shown to influence FVIII, VWF, fibrinogen (Fbg), and ADAMTS13 (A disintegrin and metalloprotease with thrombospondin type 1 motif, 13). We investigated the effects of ABO type, age, and gender on plasma levels of FVIII, Fbg, VWF, and ADAMTS13 in a Chinese population.MethodsA total of 290 healthy volunteers were eligible for this study. ABO blood group was determined by indirect technique. FVIII:C and Fbg were measured by clotting assays. VWF antigen (VWF:Ag), collagen-binding activity (VWF:CBA), and ADAMTS13 antigen were assessed by ELISA, whereas VWF ristocetin cofactor activity (VWF:Rcof) was performed by agglutination of platelets with ristocetin.ResultsMean FVIII:C and VWF levels (VWF:Ag, VWF:CBA, and VWF:Rcof) were significantly higher in non-O than in O type subjects (p < 0.05 for all comparison). ADAMTS13 antigen decreased with increasing age, whereas the other parameters increased. Other than ADAMTS13 (p < 0.01), no gender-related variations were observed in the other parameters. Moreover, FVIII:C, Fbg, VWF:Ag, VWF:CBA, and VWF:Rcof showed significant and positive relationships with age (r = 0.421, 0.445, 0.410, 0.401, and 0.589, resp.; allp < 0.001), whereas a negative relationship was observed for ADAMTS13 antigen (r = 0.306;p = 0.006). Furthermore, FVIII:C were strongly correlated with VWF:Ag, VWF:CBA, and VWF:Rcof (r = 0.746,r = 0.746, andr = 0.576, resp.;p < 0.0001). VWF parameters were also strongly correlated with each other (r = 0.0.847 for VWF:Ag and VWF:CBA;r = 0.722 for VWF:Ag and VWF:Rcof;p < 0.0001).ConclusionsABO blood group, age, and gender showed different effects on plasma levels of FVIII:C, Fbg, VWF:Ag, VWF:CBA, VWF:Rcof, and ADAMTS13 antigen. These new data on a Chinese population are quite helpful to compare with other ethnic groups.

scholarly journals ABO blood group, glycosyltransferase activity and risk of Venous Thrombosis

2020 ◽  
Author(s):  
Manal Ibrahim Kosta ◽  
Pascal Bailly ◽  
Monique Silvy ◽  
Noemie Saut ◽  
Pierre Suchon ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Blood Group ◽  
Plasma Levels ◽  
Blood Groups ◽  
Abo Blood Group ◽  
Abo Blood Groups ◽  
Factor Assay ◽  
Von Willebrand ◽  
First Time ◽  
Willebrand Factor

AbstractIntroductionABO blood group influence the risk of venous thrombosis (VT) by modifying A and B glycosyltransferases (AGT and BGT) activities that further modulates Factor VIII (FVIII) and von Willebrand Factor (VWF) plasma levels. The aim of this work was to evaluate the association of plasma GTs activities with VWF/FVIII plasma levels and VT risk in a case-control study.Materials and Methods420 cases were matched with 420 controls for age and ABO blood group. GT activities in plasma were measured using the quantitative transfer of tritiated N-acetylgalactosamine or galactose to the 2’-fucosyl-lactose and expressed in disintegration per minute/30µL of plasma and 2 hours of reaction (dpm/30µL/2H). FVIII and VWF plasma levels were respectively measured using human FVIII-deficient plasma in a 1-stage factor assay and STA LIATEST VWF (Diagnostica Stago).ResultsA and B GT activities were significantly lower in cases than in controls (8119±4027 vs 9682±4177 dpm/30µL/2H, p=2.03 × 10−5, and 4931±2305 vs 5524±2096 dpm/30µL/2H, p=0.043 respectively). This association was observed whatever the ABO blood groups. The ABO A1 blood group was found to explain∼80% of AGT activity. After adjusting for ABO blood groups, AGT activity was not correlated to VWF/FVIII plasma levels. Conversely, there was a moderate correlation (ρ∼0.30) between BGT activity and VWF/ FVIII plasma levels in B blood group carriers.ConclusionThis work showed, for the first time, that GT activities were decreased in VT patients in comparison to controls with the same ABO blood group. The biological mechanisms responsible for this association remained to be determined.

scholarly journals Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients

Blood ◽  
2019 ◽  
Vol 134 (11) ◽  
pp. 880-891 ◽  
Author(s):  
Laura L. Swystun ◽  
Kenichi Ogiwara ◽  
Orla Rawley ◽  
Christine Brown ◽  
Ilinca Georgescu ◽  
...  
Keyword(s):  
Blood Group ◽  
Von Willebrand Factor ◽  
Half Life ◽  
Hemophilia A ◽  
Blood Type ◽  
Abo Blood Group ◽  
Genetic Determinants ◽  
Group Status ◽  
Von Willebrand ◽  
Willebrand Factor

Abstract Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability in hemophilia A patients. Although previous studies have determined that age, body mass index, von Willebrand factor antigen (VWF:Ag) levels, and ABO blood group status can influence FVIII PK, they do not account for all observed variability. In this study, we aim to describe the genetic determinants that modify the FVIII PK profile in a population of 43 pediatric hemophilia A patients. We observed that VWF:Ag and VWF propeptide (VWFpp)/VWF:Ag, but not VWFpp, were associated with FVIII half-life. VWFpp/VWF:Ag negatively correlated with FVIII half-life in patients with non-O blood type, but no correlation was observed for type O patients, suggesting that von Willebrand factor (VWF) half-life, as modified by the ABO blood group, is a strong regulator of FVIII PK. The FVIII-binding activity of VWF positively correlated with FVIII half-life, and the rare or low-frequency nonsynonymous VWF variants p.(Arg826Lys) and p.(Arg852Glu) were identified in patients with reduced VWF:FVIIIB but not VWF:Ag. Common variants at the VWF, CLEC4M, and STAB2 loci, which have been previously associated with plasma levels of VWF and FVIII, were associated with the FVIII PK profile. Together, these studies characterize the mechanistic basis by which VWF clearance and ABO glycosylation modify FVIII PK in a pediatric population. Moreover, this study is the first to identify non-VWF and non-ABO variants that modify FVIII PK in pediatric hemophilia A patients.

ABO Blood Group Genotype and Plasma von Willebrand Factor in Normal Individuals

Vox Sanguinis ◽  
1995 ◽  
Vol 68 (4) ◽  
pp. 236-240 ◽  
Author(s):  
Masayuki Shima ◽  
Yoshihiro Fujimura ◽  
Takayuki Nishiyama ◽  
Tomomi Tsujiuchi ◽  
Nobuhiro Narita ◽  
...  
Keyword(s):  
Blood Group ◽  
Von Willebrand Factor ◽  
Abo Blood Group ◽  
Normal Individuals ◽  
Von Willebrand ◽  
Willebrand Factor

scholarly journals Effect of ABO blood group on the collagen-binding assay for von Willebrand factor

2002 ◽  
Vol 71 (3) ◽  
pp. 229-231 ◽  
Author(s):  
Erin Haley ◽  
Nadiya Babar ◽  
Cory Ritter ◽  
Katharine A. Downes ◽  
Deana Green ◽  
...  
Keyword(s):  
Blood Group ◽  
Von Willebrand Factor ◽  
Binding Assay ◽  
Abo Blood Group ◽  
Collagen Binding ◽  
Von Willebrand ◽  
Willebrand Factor

ABO Blood Group Antigens on Human Plasma von Willebrand Factor After ABO-Mismatched Bone Marrow Transplantation

Blood ◽  
1999 ◽  
Vol 94 (8) ◽  
pp. 2895-2900 ◽  
Author(s):  
Taei Matsui ◽  
Taketo Shimoyama ◽  
Masanori Matsumoto ◽  
Yoshihiro Fujimura ◽  
Yoshinobu Takemoto ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Endothelial Cells ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Stem Cell Transplantation ◽  
Blood Group ◽  
Abo Blood Group ◽  
Blood Group Antigens ◽  
Von Willebrand ◽  
Willebrand Factor

von Willebrand factor (vWF) is synthesized exclusively by endothelial cells and megakaryocytes, and stored in the intracellular granules or constitutively secreted into plasma. ABO blood group antigens are covalently associated with asparagine-linked sugar chains of plasma vWF. The effect of ABO-mismatched bone marrow transplantation (BMT) or blood stem cell transplantation (BSCT) on the expression of ABO blood group antigens on the vWF was examined to obtain information on the origin of these antigens. In ABO-mismatched (HLA-matched) groups, 8 cases of BMT and 4 cases of BSCT were examined. In all cases, the ABO blood groups on red blood cells were gradually converted to the donor’s type within 80 to 90 days after the transplantation. The blood group antigens on the vWF were consistent with the recipient’s blood group for the period monitored by enzyme-linked immunosorbent assay (ELISA). When vWF was isolated from normal platelets and examined for the blood group antigens using ELISA or immunoblotting, it showed few antigens. However, vWF extracted from veins expressed blood group antigens. These findings indicate that platelet (megakaryocyte)-derived vWF does not contain blood group antigens and that these antigens may be specifically associated with vWF synthesized in endothelial cells and secreted into plasma. Furthermore, it is possible that the persistence of the recipient’s blood group antigens on plasma glycoproteins such as vWF, independent of the donor-derived erythrocytes, after ABO-mismatched stem cell transplantation, may influence the immunological system in the production of anti-blood group antibodies resulting in the establishment of immunological tolerance in the recipient plasma.

Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group

Blood ◽  
2006 ◽  
Vol 109 (7) ◽  
pp. 2840-2846 ◽  
Author(s):  
James Anthony Davies ◽  
Peter William Collins ◽  
Lee Sarah Hathaway ◽  
Derrick John Bowen
Keyword(s):  
Blood Group ◽  
Von Willebrand Factor ◽  
Qualitative Difference ◽  
Binding Activity ◽  
Abo Blood Group ◽  
Entire Cohort ◽  
And Function ◽  
Von Willebrand ◽  
Willebrand Factor

Abstract Blood group O and the cysteine allele of the Y/C1584 change in von Willebrand factor (VWF) are enriched in type 1 VWD, but neither causes disease. We investigated the effect of C1584, alone and in combination with the ABO blood group, on the level and properties of plasma VWF. A cohort of 5052 blood donors was recruited: 50 donors were heterozygous for Y/C1584 and 5002 were homozygous for Y/Y1584. Mean VWF antigen (VWF:Ag) for heterozygotes (82 ± 35 IUdL−1) was significantly lower than for homozygotes (111 ± 37 IUdL−1) (P < .001). For each ABO blood group, VWF:Ag was decreased among Y/C1584 heterozygotes compared with Y/Y1584 homozygotes; a larger decrease was observed for group O. Among donors with VWF:Ag levels of 50 IUdL−1 or lower, Y/C1584 heterozygosity was markedly enriched (18%) compared with the entire cohort (1.5%). Blood group O was enriched to a lesser extent (2.4%), but Y/C1584 in conjunction with group O was strikingly enriched (34.8%). VWF collagen binding activity (VWF:CB) and ristocetin cofactor activity (VWF:RCo) were significantly lower for Y/C1584 heterozygotes than for Y/Y1584 homozygotes, and a qualitative difference in Y/C1584 plasma VWF multimer profile was observed compared with that for Y/Y1584 VWF. The data support a multifactorial basis for low VWF levels in some individuals.

Sign in / Sign up

Export Citation Format

Share Document